Expectations, validity, and reality in pharmacogenetics

Journal of Clinical Epidemiology

Volumn 63, Issue 9, 2010, Pages 960-969

  Limdi, Nita A ^a   Veenstra, David L ^b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

B*1502; Carbamazepine; CYP2C9; CYP2D6; HLA; Pharmacogenetics; Tamoxifen; Warfarin

Indexed keywords

ANASTROZOLE; CARBAMAZEPINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; HLA B ANTIGEN; LETROZOLE; PIPENDOXIFENE; TAMOXIFEN; WARFARIN; ANTICOAGULANT AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BLEEDING; BREAST CANCER; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; ENDOMETRIUM CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSENSITIVITY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VAGINA BLEEDING; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG MONITORING; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; PERSONALIZED MEDICINE; PROCEDURES; STANDARDS;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY; GENETIC VARIATION; GENOTYPE; HEMORRHAGE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; STEVENS-JOHNSON SYNDROME; TAMOXIFEN; WARFARIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

EID: 77955653161     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2009.09.006     Document Type: Review

References (66)

1. D.S. Budnitz, N. Shehab, S.R. Kegler, and C.L. Richards Medication use leading to emergency department visits for adverse drug events in older adults Ann Intern Med 147 2007 755 765
2. J. Lazarou, B.H. Pomeranz, and P.N. Corey Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1998 1200 1205
3. T.J. Moore, M.R. Cohen, and C.D. Furberg Serious adverse drug events reported to the Food and Drug Administration, 1998-2005 Arch Intern Med 167 2007 1752 1759
4. M. Ingelman-Sundberg Pharmacogenomic biomarkers for prediction of severe adverse drug reactions N Engl J Med 358 2008 637 639
5. P. Manunta, and G. Bianchi Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives-the adducin paradigm J Am Soc Nephrol 17 2006 S30 S35
6. B.R. Davis, D.K. Arnett, E. Boerwinkle, C.E. Ford, C. Leiendecker-Foster, M.B. Miller, et al. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study Pharmacogenomics J 7 2007 112 122
7. T. Gerhard, Y. Gong, A.L. Beitelshees, X. Mao, M.T. Lobmeyer, R.M. Cooper-DeHoff, et al. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES) Am Heart J 156 2008 397 404
8. H. Schelleman, O.H. Klungel, J.C. Witteman, A. Hofman, C.M. van Duijn, A. de Boer, et al. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure Eur J Hum Genet 14 2006 860 866
9. S.M. Boekholdt, F.M. Sacks, J.W. Jukema, J. Shepherd, D.J. Freeman, A.D. McMahon, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects Circulation 111 2005 278 287
10. P.B. Mellen, and D.M. Herrington Pharmacogenomics of blood pressure response to antihypertensive treatment J Hypertens 23 2005 1311 1325
11. J.M. Ferdinands, D.M. Mannino, M.L. Gwinn, and M.S. Bray ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study PLoS One 2 3 2007 e289
12. K.G. Tantisira, and S.T. Weiss The pharmacogenetics of asthma: an update Curr Opin Mol Ther 7 2005 209 217
13. D.S. Feldman, C.A. Carnes, W.T. Abraham, and M.R. Bristow Mechanisms of disease: beta-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure Nat Clin Pract Cardiovasc Med 2 2005 475 483
14. E.B. Binder, and F. Holsboer Pharmacogenomics and antidepressant drugs Ann Med 38 2006 82 94
15. D.B. Matchar, M.E. Thakur, I. Grossman, D.C. McCrory, L.A. Orlando, D.C. Steffens, et al. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs) Evid Rep Technol Assess (Full Rep) 146 2007 1 77
16. J.P. Ioannidis, J. Bernstein, P. Boffetta, J. Danesh, S. Dolan, P. Hartge, et al. A network of investigator networks in human genome epidemiology Am J Epidemiol 162 2005 302 304
17. J.P. Ioannidis, M. Gwinn, J. Little, J.P. Higgins, J.L. Bernstein, P. Boffetta, et al. A road map for efficient and reliable human genome epidemiology Nat Genet 38 2006 3 5
18. M.J. Khoury, J. Little, J. Higgins, J.P. Ioannidis, and M. Gwinn Reporting of systematic reviews: the challenge of genetic association studies PLoS Med 4 6 2007 e211
19. T.E. Klein, R.B. Altman, N. Eriksson, B.F. Gage, S.E. Kimmel, M.T. Lee, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 2009 753 764
20. K. McGeechan, P. Macaskill, L. Irwig, G. Liew, and T.Y. Wong Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide Arch Intern Med 168 2008 2304 2310
21. N.A. Limdi, and D.L. Veenstra Warfarin pharmacogenetics Pharmacotherapy 28 2008 1084 1097
22. G.M. Cooper, J.A. Johnson, T.Y. Langaee, H. Feng, I.B. Stanaway, U.I. Schwarz, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose Blood 112 2008 1022 1027
23. N.A. Limdi, T.M. Beasley, M.R. Crowley, J.A. Goldstein, M.J. Rieder, D.A. Flockhart, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Pharmacogenomics 9 2008 1445 1458
24. J.L. Anderson, B.D. Horne, S.M. Stevens, A.S. Grove, S. Barton, Z.P. Nicholas, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2007 2563 2570
25. T. Schalekamp, B.P. Brasse, J.F. Roijers, Y. Chahid, J.H. van Geest-Daalderop, H. de Vries-Goldschmeding, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation Clin Pharmacol Ther 80 2006 13 22
26. T. Schalekamp, B.P. Brasse, J.F. Roijers, E. van Meegen, F.J. van der Meer, E.M. van Wijk, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement Clin Pharmacol Ther 81 2007 185 193
27. T. Schalekamp, M. Oosterhof, E. van Meegen, F.J. van Der Meer, J. Conemans, M. Hermans, et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status Clin Pharmacol Ther 76 2004 409 417
28. T. Schalekamp, J.H. van Geest-Daalderop, H. de Vries-Goldschmeding, J. Conemans, M. Bernsen Mj, and A. de Boer Acenocoumarol stabilization is delayed in CYP2C93 carriers Clin Pharmacol Ther 75 2004 394 402
29. H. Schelleman, Z. Chen, C. Kealey, A.S. Whitehead, J. Christie, M. Price, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians Clin Pharmacol Ther 81 2007 742 747
30. J. Taube, D. Halsall, and T. Baglin Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment Blood 96 2000 1816 1819
31. U.I. Schwarz, M.D. Ritchie, Y. Bradford, C. Li, S.M. Dudek, A. Frye-Anderson, et al. Genetic determinants of response to warfarin during initial anticoagulation N Engl J Med 358 2008 999 1008
32. G.P. Aithal, C.P. Day, P.J. Kesteven, and A.K. Daly Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 1999 717 719
33. M. Margaglione, D. Colaizzo, G. D'Andrea, V. Brancaccio, A. Ciampa, E. Grandone, et al. Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 2000 775 778
34. M.K. Higashi, D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, S.L. Srinouanprachanh, F.M. Farin, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
35. N.A. Limdi, G. McGwin, J.A. Goldstein, T.M. Beasley, D.K. Arnett, B.K. Adler, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin Clin Pharmacol Ther 83 2008 312 321
36. L.M. Meckley, A.K. Wittkowsky, M.J. Rieder, A.E. Rettie, and D.L. Veenstra An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thromb Haemost 100 2008 229 239
37. M.H. Eckman, J. Rosand, S.M. Greenberg, and B.F. Gage Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation Ann Intern Med 150 2009 73 83
38. L.J. Lesko The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics Clin Pharmacol Ther 84 2008 301 303
39. A. McWilliam, R. Lutter, and C. Nardinelli Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin Per Med 5 2008 279 284
40. J.C. Roujeau, and R.S. Stern Severe adverse cutaneous reactions to drugs N Engl J Med 331 1994 1272 1285
41. B. Gerdts, A.F. Vloemans, and R.W. Kreis Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre J Eur Acad Dermatol Venereol 21 2007 781 788
42. G. Gravante, D. Delogu, M. Marianetti, M. Trombetta, G. Esposito, and A. Montone Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome Eur Rev Med Pharmacol Sci 11 2007 119 127
43. W.H. Chung, S.I. Hung, H.S. Hong, M.S. Hsih, L.C. Yang, H.C. Ho, et al. Medical genetics: a marker for Stevens-Johnson syndrome Nature 428 2004 486
44. J.C. Roujeau The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification J Invest Dermatol 102 1994 28S 30S
45. S.I. Hung, W.H. Chung, S.H. Jee, W.C. Chen, Y.T. Chang, W.R. Lee, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions Pharmacogenet Genomics 16 2006 297 306
46. C. Lonjou, L. Thomas, N. Borot, N. Ledger, C. de Toma, H. LeLouet, et al. A marker for Stevens-Johnson syndrome: ethnicity matters Pharmacogenomics J 6 2006 265 268
47. A. Alfirevic, A.L. Jorgensen, P.R. Williamson, D.W. Chadwick, B.K. Park, and M. Pirmohamed HLA-B locus in Caucasian patients with carbamazepine hypersensitivity Pharmacogenomics 7 2006 813 818
48. P.B. Ferrell Jr., and H.L. McLeod Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations Pharmacogenomics 9 2008 1543 1546
49. W. Loscher, U. Klotz, F. Zimprich, and D. Schmidt The clinical impact of pharmacogenetics on the treatment of epilepsy Epilepsia 50 2009 1 23
50. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
51. S. Borges, Z. Desta, L. Li, T.C. Skaar, B.A. Ward, A. Nguyen, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 2006 61 74
52. M.P. Goetz, S.K. Knox, V.J. Suman, J.M. Rae, S.L. Safgren, M.M. Ames, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 2007 113 121
53. W. Schroth, L. Antoniadou, P. Fritz, M. Schwab, T. Muerdter, U.M. Zanger, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 2007 5187 5193
54. M.P. Goetz, J.M. Rae, V.J. Suman, S.L. Safgren, M.M. Ames, D.W. Visscher, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 2005 9312 9318
55. A. Howell, J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J.F. Forbes, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
56. R.S. Punglia, H.J. Burstein, E.P. Winer, and J.C. Weeks Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis J Natl Cancer Inst 100 2008 642 648
57. S.A. Nowell, J. Ahn, J.M. Rae, J.O. Scheys, A. Trovato, C. Sweeney, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 2005 249 258
58. P. Wegmen, S. Elingarami, J. Carstensen, O. Stål, B. NordenskjÖld, and S. Wingren Genetic vatiants of CYP3A5, CYP2D6, SULT1A1, UGT2B15, and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 1 2007 R7
59. J. Rae, and M.S Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Pharmacogenomics J 4 2009 258 264
60. D.F. Hayes, V. Stearns, J. Rae, and D. Flockhart A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst 100 2008 610 613
61. M.I. McCarthy, and J.N. Hirschhorn Genome-wide association studies: potential next steps on a genetic journey Hum Mol Genet 17 2008 R156 R165
62. D.B. Goldstein, S.K. Tate, and S.M. Sisodiya Pharmacogenetics goes genomic Nat Rev Genet 4 2003 937 947
63. M.E. Sarasquete, R. García-Sanz, L. Marín, M. Alcoceba, M.C. Chillón, A. Balanzategui, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis Blood 112 2008 2709 2712
64. T. Inada, M. Koga, H. Ishiguro, Y. Horiuchi, A. Syu, T. Yoshio, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia Pharmacogenet Genomics 18 2008 317 323
65. D.A. Garcia Warfarin and pharmacogenomic testing: the case for restraint Clin Pharmacol Ther 84 2008 303 305
66. S.D. Fihn, M. McDonell, D. Martin, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group Ann Intern Med 118 1993 511 520